What Alzheimercentrum Amsterdam does

Alzheimercentrum Amsterdam is a specialized memory clinic and research center embedded within Amsterdam UMC (location VUmc), founded in 2000 by Prof. Philip Scheltens. The center diagnoses and treats patients with suspected dementia and cognitive complaints, with a particular focus on young-onset dementia, operating a comprehensive one-day diagnostic screening program that combines neuropsychological evaluation, MRI, EEG, and lumbar puncture. It serves thousands of patients annually referred from across the Netherlands via general practitioners and medical specialists, and provides second opinion services, support groups, and patient education through its Mijn Dossier portal and HersenHelden podcast.

The center maintains the Amsterdam Dementia Cohort, a longitudinal research database of nearly 7,000 individuals established in 2000 with annual follow-up visits, and conducts pharmaceutical clinical trials through the Brain Research Center. Its proprietary technology assets include the Amsterdam IADL Questionnaire (an adaptive computerized functional assessment tool), the ADappt shared decision-making toolkit with CSF/MRI interpretation calculator, and the Neurochemisch Laboratorium, a reference laboratory for the International Alzheimer Quality Control program across amyloid beta 1-42, total tau, and P-tau 181 biomarkers.

Alzheimercentrum Amsterdam operates as a non-profit unit funded through three streams: Dutch Zorgverzekeringswet reimbursements for clinical services, donations via Stichting Steun Alzheimercentrum Amsterdam, and pharmaceutical clinical trial contracts. Its go-to-market is exclusively referral-driven through the Dutch healthcare system; self-referral is not possible. The center has over 100 multidisciplinary staff and is led by Prof. dr. Wiesje van der Flier (scientific director), Prof. dr. Yolande Pijnenburg (medical director), and director Jort Vijverberg, with research embedded within Amsterdam Neuroscience.

Name

Alzheimercentrum Amsterdam

Legal name

Alzheimercentrum Amsterdam

Website

https://alzheimercentrum.nl

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

Alzheimercentrum Amsterdam is a non-profit memory clinic within Amsterdam UMC that diagnoses and treats dementia, runs the Amsterdam Dementia Cohort of nearly 7,000 patients, conducts pharmaceutical clinical trials, and serves referred patients across the Netherlands.

Ownership category

akta.pro rank

Product category

Dementia diagnostic and treatment services

NAICS

Services for the Elderly and Persons with Disabilities (624120)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093), Services-Medical Laboratories (8071)

akta.pro primary industry

Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)

akta.pro secondary industries

Dementia/Alzheimer’s Care Management & Behavioral Support (HLADALAF), Memory Care Care Management & Navigation (Dementia Care Coordination) (HLADACAJ)

Keywords

• Dementia diagnostics
• Memory clinic services
• Neurological clinical research
• Biomarker analysis services
• Clinical trial operations

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Healthcare Service Reimbursement: As part of Amsterdam UMC, the center generates revenue through reimbursement for clinical diagnostic and treatment services covered under the Dutch national health insurance system (Zorgverzekeringswet). Patients are seen through the healthcare system, with costs covered by health insurers.
2. Donations and Charitable Contributions: The center raises funds through donations from individuals, corporate donors, and patient networks. IBAN NL 42 INGB 0006 9052 76. Support mechanisms include one-time donations, periodic gifts (periodieke schenking), membership in donor networks (Genootschap, REmember), legacy bequests (nalaten), and event-based fundraising.
3. Clinical Trial Revenue: The center conducts pharmaceutical clinical trials through the Brain Research Center, testing medications for patients with mild cognitive impairment and various forms of dementia. These trials generate revenue through contracts with pharmaceutical companies.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Alzheimercentrum Amsterdam is the specialized diagnostic, treatment, and research center for Alzheimer's and dementia within Amsterdam UMC (location VUmc). It delivers a one-day comprehensive diagnostic screening (Screeningsdag) covering neuropsychological assessment, MRI, EEG, and lumbar puncture, supported by CSF biomarker analysis in its reference-grade Neurochemisch Laboratorium. The center also runs proprietary diagnostic tools (A-IADL-Q, ADappt), the Amsterdam Dementia Cohort research database, pharmaceutical clinical trials via the Brain Research Center, the Mijn Dossier patient portal, and the Hersenonderzoek.nl research participation platform.

Product overview

Alzheimercentrum Amsterdam operates as a diagnostic and treatment center for dementia affiliated with Amsterdam UMC, offering a portfolio of patient-facing digital services and clinical programs. Key offerings include the Mijn Dossier patient portal for accessing medical records, the Hersenonderzoek.nl research participation platform, and the ADappt diagnostic communication toolkit. The center provides specialized diagnostic services including the Screeningsdag (one-day screening program), Neurochemisch Laboratorium for biomarker analysis, and the Brain Research Center for clinical drug trials. The Amsterdam IADL Questionnaire is a computerized assessment tool for evaluating daily living impairments in early dementia. The center also maintains the Amsterdam Dementia Cohort, a research database of nearly 7,000 patients supporting ongoing scientific research. Clinical services are complemented by educational programs like the annual Dementie Update professional training.

Differentiator

Problem solved

Functional benefit

Products and services

• Screeningsdag (Screening Day) A comprehensive one-day diagnostic program in which multiple examinations are conducted to establish a dementia diagnosis. Patients are assessed by an assistant physician, nursing consultant, neuropsychologist, and neurologist in a single hospital visit, including neuropsychological evaluation, MRI, EEG, and lumbar puncture.
• Neurochemisch Laboratorium (Neurochemical Laboratory) Specialized laboratory within Amsterdam UMC that analyzes Alzheimer biomarkers in cerebrospinal fluid: amyloid beta 1-42, total tau, and hyperphosphorylated tau 181. Functions as a reference laboratory for the International Alzheimer Quality Control study. Used by referring clinicians and the center's own diagnostic program.
• Second Opinion Service Consultation service providing expert advice on diagnosis or treatment from a physician not currently treating the patient, supporting informed decision-making for patients with dementia or suspected dementia.
• Mijn Dossier Secure digital patient portal that allows patients to access their medical records, view test results, manage appointments, send secure messages to their care team, and review correspondence from their physicians.
• Hersenonderzoek.nl An online platform where healthy individuals and patients can register interest in participating in brain research, connecting researchers with potential study participants to accelerate dementia research.
• Amsterdam IADL Questionnaire (A-IADL-Q) An adaptive and computerized caregiver-completed questionnaire designed to assess impairments in instrumental activities of daily living (IADL) in early dementia. Available in a full version (70 items, 7 categories, ~20-25 minutes) and a short version A-IADL-Q-SV (30 items, ~10 minutes).
• ADappt Toolkit An online toolkit that supports communication about diagnostics at memory clinics, helping clinicians discuss diagnostic testing options with patients and make shared decisions. Includes a calculation tool for unambiguous interpretation of MRI and protein markers in cerebrospinal fluid for MCI patients.
• Brain Research Center A specialized facility for conducting pharmaceutical drug trials in patients with mild cognitive impairment and various forms of dementia, operating in partnership with the Industry Alliance Office of Amsterdam Neuroscience.
• Amsterdam Dementia Cohort A research cohort of nearly 7,000 individuals who have visited the Alzheimer Center Amsterdam. Participants undergo comprehensive one-day screening including neuropsychological evaluation, MRI, EEG, and lumbar puncture, with annual follow-up visits, supporting scientific research into dementia.
• HalloHersenen A website and app that provided daily tips for brain health ('Oppeppers') and information about lifestyle and healthy brains, developed in collaboration with Trinity College Dublin under the EuroSCD project. The Dutch platform is no longer available, but international versions remain accessible at hellobrain.eu.

Quantifiable outcome

• Nearly 7,000 individuals in the Amsterdam Dementia Cohort with longitudinal follow-up data
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Amsterdam NeurosciencecoreStrategic or Co-development PartnerScientific research at Alzheimercentrum Amsterdam is embedded within Amsterdam Neuroscience, the overarching body for all neuroscientists at the VU. This institutional partnership enables direct translation of fundamental research insights into clinical practice and provides access to a broad network of neuroscience researchers.
• Brain Research Center (Amsterdam UMC)coreStrategic or Co-development PartnerThe Brain Research Center handles the execution of drug trials (medicijn onderzoek) at the center, supporting the third research line of Intervention & Prevention. It is the operational arm for pharmaceutical clinical trials.
• Industry Alliance Office of Amsterdam NeuroscienceminorStrategic or Co-development PartnerThe center collaborates with the Industry Alliance Office of Amsterdam Neuroscience for the Intervention & Prevention research line, particularly for drug development partnerships with pharmaceutical companies.
• Trinity College DublinminorStrategic or Co-development PartnerDuring the development of the HalloHersenen website and app, the center collaborated with researchers at Trinity College Dublin who had developed texts about the brain and brain health within a European project.
• EuroSCD Consortium (University of Cologne, Hospital Clinic Barcelona)minorStrategic or Co-development PartnerThe EuroSCD-project was a collaboration between University of Cologne (Germany), Hospital Clinic Barcelona (Spain), and Alzheimercentrum Amsterdam. The project investigated the relationship between lifestyle and healthy brains in people with memory complaints, including development of the HalloHersenen app.
• Kenniscentrum Dementie op Jonge LeeftijdminorStrategic or Co-development PartnerThis knowledge center for young-onset dementia promotes excellent care and support for young people with dementia. Healthcare professionals from organizations across the Netherlands are affiliated members. The center refers patients to this resource for questions about care facilities, day care locations, peer support, and diagnosis at young age.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Mayo Clinic Alzheimer's Disease Research Center: US academic Alzheimer's research center within a major health system; comparable integrated model combining memory-clinic care, longitudinal cohorts, biomarker research, and clinical trials at scale.
• German Center for Neurodegenerative Diseases (DZNE): Larger national German research organization dedicated to neurodegenerative disease; broader scope and multiple sites but highly comparable research focus on dementia biomarkers, cohorts, and translational programs.
• Amsterdam UMC: Parent university medical center formed from VUmc and AMC; provides the institutional infrastructure, Neurology department, and clinical trial environment within which Alzheimercentrum Amsterdam operates, and houses related neuroscience programs.

Direct peers

• UCL Dementia Research Centre: UK academic dementia research center at Queen Square; runs similarly structured memory-clinic services, large longitudinal cohorts, and pharma-sponsored trials, making it one of the closest international academic comparables.
• Erasmus MC Alzheimercentrum: Academic memory clinic at Erasmus University Medical Center Rotterdam; one of the other major Dutch specialist dementia diagnostic and research centers offering comparable one-stop diagnostic screening and clinical research programs.
• Maastricht UMC+ Alzheimer Centrum Limburg: Academic memory clinic embedded in Maastricht UMC+ focused on dementia diagnosis and research; comparable operating model combining clinical referral pathways, biomarker diagnostics, and clinical trial execution within a Dutch university hospital.
• Radboudumc Alzheimer Centrum: Dementia research and diagnostic center at Radboud University Medical Center in Nijmegen; another Dutch academic peer running parallel memory-clinic services, biomarker research, and clinical trial programs.
• Brain Research Center: Sister organization within Amsterdam UMC that operationalizes pharmaceutical clinical trials for MCI and dementia; directly comparable clinical-trial execution capability and overlapping investigator network.
• Karolinska Institutet – Center for Alzheimer Research: Swedish academic dementia research center embedded in a university hospital; comparable integrated care-and-research model with biomarker analysis and clinical trial activity.

Others

• Alzheimer Nederland: Dutch national patient advocacy and fundraising organization for dementia; not a clinical peer but a closely linked ecosystem partner that funds dementia research, supports patient networks, and co-drives awareness across the Netherlands.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AlzheimerAms
• LinkedInlinkedin.com/company/amsterdam-umc-alzheimercentrum-amsterdam
• Facebookfacebook.com/AlzheimercentrumAmsterdam

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alzheimercentrum Amsterdam